InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） (1)2025年第三季度季度報告 及 (2)提名委員會組成變動 本 公 告 乃 由 諾 誠 健 華 醫 藥 有 限 公 司（「本公司」，連 同 其 附 屬 公 司 統 稱「本 集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 13.09(2)(a)條及第13.10B條及香港法例第571章證券及期貨條例第XIVA部的內幕 消息條文作出。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 2025年第三季度季度報告 茲載列本公司在上海證券交易所網站刊發的《諾誠健華醫藥有限公司2025年第 三季度報告》（「2025年第三季度報告」），僅供參閱。以下為本公司2025年第三 季度報告的原文，僅供參考。如有任何歧義，概以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒 ...

关于调整董事会提名委员会成员的公告 诺诚健华医药有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-038 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | | | 调整前 | Jisong | Cui（崔霁松）博士（主席）、胡兰女士、 | | --- | --- | --- | --- | | 董事会提名 | | 董丹丹博士 | | | 委员会 | 调整后 | Jisong | Cui（崔霁松）博士（主席）、董丹丹博士、 | | | | Kunliang | Guan（管坤良）教授 | 特此公告。 诺诚健华医药有限公司董事会 2025 年 11 月 14 日 1 诺诚健华医药有限公司（以下简称"公司"）于 2025 年 11 月 13 日召开董事 会，审议通过《提名委员会成员变动》的议案，现将有关情况公告如下： 鉴于香港联交所上市规则附录 C1 所载企业管治守则的修 ...

Core Viewpoint - Nocera Biopharma (688428) reported significant revenue growth and reduced net loss in Q3 2025, indicating a positive trajectory towards profitability and sustainable growth [1] Financial Performance - The company achieved a revenue of 1.115 billion yuan in the first three quarters, representing a year-on-year increase of 59.85% [1] - The net loss for the same period was 72 million yuan, which is a 74.78% reduction compared to the previous year [1] Revenue Drivers - The revenue growth was primarily driven by the continued sales increase of the core product, BTK inhibitor Acalabrutinib (Yinokai), and an upfront payment from a licensing agreement with Prolium [1] - Acalabrutinib's revenue for the first three quarters rose by 45.8% year-on-year, reaching 1.01 billion yuan, surpassing the total revenue of the previous year [1] Future Outlook - The company anticipates achieving breakeven for the full year 2025, two years ahead of its profitability target, supported by strong revenue growth, strict cost management, and a significant licensing deal with Zenas in early October [1] - This positions the company well for sustainable profitability and accelerated globalization [1]

Financial Performance - The total operating revenue for the first nine months of 2025 reached RMB 1.115 billion, an increase of 59.85% compared to the same period last year, with a gross margin of 88.8%, up 2.8 percentage points from 86.0%[4] - Sales revenue from the core product, Orelabrutinib (宜诺凯®), amounted to RMB 1.010 billion for the first nine months of 2025, representing a year-on-year growth of 45.77%[5] - The company reported a significant increase in operating revenue, primarily due to the continuous increase in sales volume of a key product, resulting in a substantial cash inflow[12] - Total revenue for the first three quarters of 2025 reached CNY 1,115,328,393.86, a significant increase of 60% compared to CNY 697,748,228.93 in the same period of 2024[21] - The company's total revenue from drug sales for the first nine months of 2025 was RMB 1.024 billion, an increase of 47.38% year-on-year[7] Expenses and Losses - The net loss for the first nine months of 2025 was RMB 72 million, a reduction of 74.78% compared to the same period last year[4] - Research and development expenses totaled RMB 676 million for the first nine months of 2025, accounting for 60.61% of operating revenue, a decrease of 27.53 percentage points year-on-year[7] - The net loss for the first three quarters of 2025 was CNY 71,950,523.03, an improvement from a net loss of CNY 285,317,584.04 in the same period of 2024[22] - The company experienced a net loss attributable to shareholders, with basic and diluted earnings per share showing a decline compared to the same period last year[12] - The company reported a basic and diluted earnings per share of CNY -0.04 for the first three quarters of 2025, compared to CNY -0.16 in 2024[22] Cash Flow and Assets - As of September 30, 2025, the company held approximately RMB 7.759 billion in cash and cash equivalents, enabling continued acceleration of pipeline project development[6] - The company's cash and cash equivalents increased to CNY 6,820,269,250.58 as of September 30, 2025, compared to CNY 6,240,825,867.22 at the end of 2024[19] - The total assets as of September 30, 2025, were CNY 9,523,812,210.96, up from CNY 9,407,493,740.91 at the end of 2024[20] - The total cash and cash equivalents at the end of the period decreased to CNY 4,382,410,146.31 from CNY 4,949,637,182.02 year-over-year[24] - The company reported a cash outflow of CNY 1,389,806,235.54 from operating activities, compared to CNY 1,220,717,440.28 in the previous year[24] Shareholder Information - The total number of shares issued by the company is 1,764,643,952, with 1,496,284,235 shares (approximately 84.79%) listed in Hong Kong and 268,359,717 shares (approximately 15.21%) listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board[13] - HKSCC NOMINEES LIMITED holds 892,010,619 shares, representing 50.549% of the total shares[16] - HHLR Fund, L.P. and its concerted parties hold 208,671,222 shares, accounting for 11.8251% of the total shares[17] - Sunny View Holdings and the Zhao family hold 144,817,893 shares, which is 8.2066% of the total shares[17] - The top ten shareholders' holdings were disclosed, with HKSCC NOMINEES LIMITED being the largest shareholder[16] Research and Development - Orelabrutinib was approved for a new indication in April 2025 for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients[5] - Research and development expenses amounted to CNY 676,047,531.53, compared to CNY 614,983,375.71 in the previous year, indicating a focus on innovation[21] - The company is actively pursuing market expansion and innovation strategies, as indicated by the increase in R&D spending and overall revenue growth[21] Government Support - The company received government subsidies amounting to RMB 28.17 million for the year-to-date period, contributing to non-operating income[10] Cash Flow Activities - The cash inflow from operating activities increased significantly, driven by higher cash receipts from product sales and upfront payments from licensing agreements[12] - In the first three quarters of 2025, the cash inflow from operating activities was CNY 1,305,468,105.49, a significant increase of 47% compared to CNY 887,581,258.65 in the same period of 2024[24] - The net cash flow from operating activities was negative at CNY -84,338,130.05, an improvement from CNY -333,136,181.63 in the previous year[24] - Cash inflow from investment activities reached CNY 8,250,925,494.08, up from CNY 4,648,580,477.88, marking a growth of 77% year-over-year[24] - The net cash flow from investment activities was CNY -321,499,940.72, a decline from CNY 1,358,936,924.87 in the same period last year[24] - Cash inflow from financing activities totaled CNY 363,355,524.15, down from CNY 1,083,202,214.00 in the previous year[24] - The net cash flow from financing activities was CNY 138,210,016.73, a recovery from CNY -261,692,786.26 in the same period of 2024[24] Accounting Standards - The company did not apply new accounting standards for the year 2025[25]

智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...

智通财经APP讯，诺诚健华(688428.SH)披露2025年第三季度报告，公司前三季度实现营收11.15亿元， 同比增长59.85%;归属于上市公司股东的净利润亏损6441万元;扣非净利润亏损1.35亿元;基本每股收 益-0.04元。 ...

Core Insights - The company, Nuo Cheng Jian Hua (688428.SH), reported a significant revenue increase of 59.85% year-on-year for the first three quarters of 2025, reaching 1.115 billion yuan [1] - Despite the revenue growth, the company recorded a net loss attributable to shareholders of 64.41 million yuan [1] - The revenue growth was primarily driven by the continued sales increase of its core product, Oubutini (Yinokai®), and the recognition of upfront payment income from a licensing agreement with Prolium [1]

Core Viewpoint - The company announced that its newly developed BCL2 inhibitor Mesutoclax and BTK inhibitor Acalabrutinib have over 20 research results selected for the 67th American Society of Hematology (ASH) Annual Meeting, highlighting significant advancements in their clinical research pipeline [1] Group 1: Mesutoclax Research Highlights - Mesutoclax has three studies selected for the ASH meeting, including a presentation on its use in treating Mantle Cell Lymphoma (MCL) and two poster presentations on its application in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Acute Myeloid Leukemia (AML) [1] Group 2: Acalabrutinib Research Highlights - Acalabrutinib has over 20 studies selected for the ASH meeting, featuring one oral presentation and more than 20 poster displays and online releases, covering various disease areas such as Marginal Zone Lymphoma (MZL), Primary Central Nervous System Lymphoma (PCNSL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), and Diffuse Large B-Cell Lymphoma (DLBCL) [1]

Core Viewpoint - The company, Innocare Pharma, will hold an investor briefing on November 14, 2025, to discuss its Q3 2025 financial results and address investor inquiries [2][3][4]. Group 1: Meeting Details - The investor briefing is scheduled for November 14, 2025, from 11:00 AM to 12:00 PM [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible online [4]. - Investors can participate in the meeting through the internet and submit questions in advance via the Roadshow Center or the company's email [5][6]. Group 2: Participants - Key participants in the meeting will include Dr. Jisong Cui (Chairman and CEO), Ms. Hu Lan (Independent Non-Executive Director), and Mr. Fu Xin (CFO) [4]. - The company may adjust the list of attendees based on special circumstances [4]. Group 3: Investor Interaction - Investors can submit questions from November 7 to November 13, 2025, before 4:00 PM [5]. - The company will respond to commonly asked questions during the briefing [3][5]. Group 4: Contact Information - For inquiries, investors can contact the domestic securities affairs department via phone or email [6]. - The details of the meeting and its main content will be available on the Roadshow Center after the event [6].

Core Insights - The company, Innovent Biologics, announced that its newly developed BCL2 inhibitor Mesutoclax and BTK inhibitor Orelabrutinib have over 20 research results selected for the 67th American Society of Hematology (ASH) Annual Meeting, including 2 oral presentations and 20 poster displays [1][2][4]. Group 1: Mesutoclax Research Highlights - Mesutoclax has three studies selected for the ASH meeting, with one oral presentation focused on its efficacy in treating relapsed/refractory mantle cell lymphoma (MCL) showing high remission rates even in patients previously resistant to BTK inhibitors [1]. - The oral presentation titled "Efficacy and tolerability of mesutoclax monotherapy in Relapsed/Refractory Mantle Cell Lymphoma patients" is scheduled for December 8, 2025 [1]. - Two poster presentations include studies on Mesutoclax's activity in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and myeloid malignancies, demonstrating encouraging efficacy and safety [2][3]. Group 2: Orelabrutinib Research Highlights - Orelabrutinib has over 20 studies selected for the ASH meeting, including one oral presentation and multiple poster displays covering various diseases such as marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL) [4][5]. - The oral presentation titled "Mid-treatment CSF ctdna and MYD88 clearance outperform PET-CT in predicting response and survival to orelabrutinib-based induction in newly diagnosed PCNSL" is scheduled for December 6, 2025 [4]. - Key poster presentations include studies on Orelabrutinib combined with other therapies for treating marginal zone lymphoma and DLBCL, indicating promising results [5][6][7]. Group 3: Company Overview - Innovent Biologics is a commercial-stage biopharmaceutical company focused on developing innovative drugs for oncology and autoimmune diseases, with multiple products in commercialization, clinical, and preclinical stages [10]. - The company has branches in major cities including Beijing, Nanjing, Shanghai, Guangzhou, Hong Kong, and the United States [10].